Cargando...
New questions regarding bioequivalence of levothyroxine preparations: A Clinician's response
A recent decision by the Food and Drug Administration (FDA) to declare various brands of levothyroxine bioequivalent has provoked objections from several physicians' organizations. These organization assert that the method of testing bioequivalence is flawed, and that indiscriminate switching a...
Gardado en:
Autor Principal: | |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado: |
Springer-Verlag
2005
|
Assuntos: | |
Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2751497/ https://ncbi.nlm.nih.gov/pubmed/16146330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/aapsj070107 |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|